New 'Schizophrenia Gene' Prompts Researchers To Test Potential Drug Target

The newfound gene, dubbed KIAA1212, serves as a bridge linking two schizophrenia genes: DISC1 and AKT. Suspecting KIAA1212 as one of many potential binding partners interacting with DISC1, whose name is an acronym for "Disrupted-in-Schizophrenia," the researchers genetically shut down the production of DISC1 proteins in newly born neurons in the hippocampus region of an adult mouse brain. The hippocampus contains a niche where native stem cells give rise to fully developed new neurons

Read : New 'Schizophrenia Gene' Prompts Researchers To Test Potential Drug Target

Now Cobroxin, available online......

In my earlier blog, I did mention about the launch of Cobroxin as OTC pain reliever. Now its available online. More...

New insight on skin pigmentation

Scientists at Karolinska Institutet in Stockholm have now shown that most melanocytes actually appear later on in foetal development from an immature cell type that exists in the skin's nerve fibres (as against reported earlier, i.e., melanocytes bud off from the spinal cord at an early foetal stage and then migrate to the skin where they remain for the rest of their lives). These cells, called Schwann cell precursors (SCPs), can also be found in adults. In addition to this, the scientists have demonstrated how neuronal damage in adults can excite the maturation of melanocytes to form hyperpigmentation around the affected nerves.

Their results also shed new light on SCP cells, which were previously seen as an immature form of supportive cells the nervous system. The researchers describe how a change in cell signalling can make the SCP cells in the skin develop into pigment cells instead, and argue that SCP cells are really a kind of stem cell. Congrats for this achievement...

Ref : http://ki.se/ki/jsp/polopoly.jsp?a=85186&d=2637&l=en&newsdep=2637

Phase III clinical study of trabedersen....

In my earlier blogs, did mention about the "antisense drugs belonging to (Geron corporation) phosphorothioate antisense oligonucleotides" . I did also mention that there are many companies working with this field (antisense). Yes now Antisense Pharma GmbH has announced that, it has received the approval by Health Canada for its pivotal Phase III clinical trial SAPPHIRE in patients with recurrent or refractory anaplastic astrocytoma. The SAPPHIRE study is a randomized, active-controlled, clinical trial designed to confirm the efficacy and safety of the investigational drug trabedersen (AP 12009 a phosphorothioate antisense oligonucleotide), observed in previous clinical studies. Trabedersen is being investigated as monotherapy compared to current standard therapy with temozolomide (alternatively BCNU (carmustine)). The results of a previous randomized, active-controlled Phase IIb study show that the novel, targeted therapy holds significant promise. Hope in the days to come, more drugs from this class of compounds...

Ref :http://www.anticancer.de/index.php?id=38.

I found this video, interesting (mode of action of trabedersen)

Researchers Discover RNA Repair System In Bacteria

Researchers Discover RNA Repair System In Bacteria

Identifying Safe Stem Cells To Repair Spinal Cords

In my earlier blog, I did mention the euphoria surrounding the stem cell and how many companies tried to fool people by claiming that, they can cure anything and everything with the help of stem cell. But this is something really interesting......

Read .....Identifying Safe Stem Cells To Repair Spinal Cords

Colcrys approved by FDA for prevention of gout flares...

Colchicine is a toxic natural product and secondary metabolite, originally extracted from plants of the genus  Colchicum (Autumn crocus, Colchicum autumnale, also known as "Meadow saffron"). It was used originally to treat rheumatic complaints, especially gout.

Recently (July 30, 2009 ), US FDA has approved Colcrys(TM) (colchicine, USP) for the prophylaxis (prevention) of gout flares. Colcrys was first approved by the FDA on for the treatment of acute gout flares when taken at the first sign of a flare. Colcrys is also indicated for the treatment of Familial Mediterranean Fever (FMF) in adults and children 4 years of age or older. Colcrys is available via prescription at pharmacies nationwide.

As per the claim by the company (URL Pharma, Inc.) , two randomized clinical trials assessed the efficacy of colchicine 0.6 mg twice a day for the prophylaxis of gout flares in patients initiating treatment with uric-acid lowering therapy. In both trials, treatment with colchicine decreased the frequency of gout flares. Colchicine has been shown to be well-tolerated when paired with uric acid-lowering agents such as allopurinol. The dosing of Colcrys for gout flare prophylaxis is one tablet (0.6 mg) once or twice a day. The maximum daily dose for prophylaxis is two tablets (1.2 mg).

Uric acid-lowering agents are highly effective and well-established in chronic gout management, but the initiation of this therapy may sometimes trigger a gout flare, where as Colchicine has been proven to be effective in preventing flares when given in conjunction with uric acid-lowering therapy, except for the mild diarrhea. Hope patients suffering from gout will breathe a sigh of relief..

Ref : http://www.drugs.com/colcrys.html

Fluarix seasonal influenza vaccine approved by the FDA

Fluarix seasonal influenza vaccine approved by the FDA

Patients with chronic hepatitis C can benefit by drinking coffee

Patients with chronic hepatitis C and advanced liver disease who drink three or more cups of coffee per day have a 53% lower risk of liver disease progression than non-coffee drinkers according to a new study. The study found that patients with hepatitis C-related bridging fibrosis or cirrhosis who did not respond to standard disease treatment benefited from increased coffee intake. An effect on liver disease was not observed in patients who drank black or green tea.

Read......

Patients with chronic hepatitis C can benefit by drinking coffee

Mangosteen Juice for diabetic obese patients?

The Purple Mangosteen (Garcinia mangostana), colloquially known simply as "the mangosteen", is a tropical evergreen tree, believed to have originated in the Sunda Islands and the Moluccas of Indonesia. The tree grows from 7 to 25 m (20–80 ft) tall. The rind (exocarp) of the edible fruit is deep reddish purple when ripe. Botanically an aril, the fragrant edible flesh can be described as sweet and tangy, citrusy with peach flavor and texture.

Mangosteen is typically advertised and marketed as part of an emerging category of novel functional foods sometimes called "superfruits" presumed to have a combination of 1) appealing subjective characteristics, such as taste, fragrance and visual qualities, 2) nutrient richness, 3) antioxidant strength and 4) potential impact for lowering risk against human diseases.

Though the antioxidant strength was known earlier, a recent study by Dr. Jay Udani and co workers is interesting and as per the claim by the authors, mangosteen juice has anti-inflammatory properties which could prove to be valuable in preventing the development of heart disease and diabetes in obese patients. For people drinking over half a liter of mangosteen juice a day, the degree of reduction in CRP levels was statistically significant – a reduction of 1.33mg/L compared to an increase of 0.9mg/L in the placebo group. Inflammation, as measured here by CRP, is a predictor of cardiovascular disease and a precursor of metabolic syndrome. Reducing inflammation in obese people is a treatment goal, and a natural treatment may be preferable to other treatments which may carry the risk of side effect. Though further studies with a larger population are required to confirm and further define the benefits of this juice, which was safe at all dosages tested its a good achievement. More...

Researchers Find Candidates For New HIV Drugs...

Researchers Find Candidates For New HIV Drugs

Shared via AddThis

Imatinib for the treatment of Scleroderma ?

We know that Imatinib (its mesylate salt, Novartis) is a drug used to treat certain types of cancer. It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other cancers. It is the first member of a new class of agents that act by inhibiting particular tyrosine kinase enzymes, instead of non-specifically inhibiting rapidly dividing cells.

More over the discovery of this compound itself is interesting & its one drug obtained via, High Throughput Screening (HTS). Chemists used a HTS of chemical libraries to identify the molecule 2-phenylaminopyrimidine. This lead compound was then tested and modified by the introduction of methyl and benzamide groups to give it enhanced binding properties, resulting in imatinib. More interesting part of this drug is a recent discovery, i.e., GLEEVEC^® (imatinib mesylate) can be used to treat Scleroderma. As per the claim by the researchers, until now no drug has been shown to be effective in treating scleroderma in a clinical trial. Several years ago, a small study provided some evidence that a chemotherapy drug called cyclophosphamide may help scleroderma patients, but the benefit was minimal and this drug causes side effects including infertility and secondary cancers.

The investigators reported an interim analysis of their results, although the study is ongoing. At one year, the investigators saw a 23 percent improvement in skin scores. The researchers also saw an improvement in forced vital capacity scores by 9.6 percent and diffusion capacity scores by 11 percent in the 18 patients who had completed one year of treatment. The lung function data was really exciting,” Dr. Spiera said. “In patients with scleroderma, you usually see lung function tests getting worse over time, and if doctors try a therapy for a year and a patient doesn’t get any worse, we get pretty excited. What is amazing to me in this study is that we actually saw improvements in both lung function tests. Congrats for this remarkable achievement.....

Ref : http://www.hss.edu/newsroom_drug-provide-treatment-scleroderma.asp

Using RNAi-based Technique, Scientists Find New Tumor Suppressor Genes In Lymphoma...

In one of my earlier blog about RNAi, I did mention about the award of USPTO notices to RXi Pharmaceuticals Corporation. But these results are really interesting, the CSHL team’s discovery stems from their use of a powerful technology called RNA interference (RNAi), which suppresses gene activity. The scientists employed RNAi to screen hundreds of candidate tumor-suppressors in living mice, using small hairpin-shaped RNA (shRNA) molecules that attach to specific genes with exquisite specificity and switch them off. In the newly reported experiments, this process revealed more than 10 genes whose deactivation accelerates the development of deadly lymphomas tumors of the immune system in the mice.

The CSHL team’s high-throughput screening strategy to functionally identify cancer genes has thus not only provided insights into cancer development but has also pointed the way toward therapeutic refinements. The team is planning a broader RNAi-based screen that will expand into other tumor models. For details...

ECG For The Mind, Could Diagnose Depression In An Hour !

Read...

ECG For The Mind' Could Diagnose Depression In An Hour....

More

Shared via AddThis